The Response of Hodgkin's Disease to Treatment with Oral Vinblastine Sulfate

doi:10.1059/0003-4819-67-2-303

The Response of Hodgkin's Disease to Treatment with Oral Vinblastine Sulfate

HENRY E. WILSON, M.D., F.A.C.P.; and
JOHN LOUIS, M.D., F.A.C.P.

Midwest Cooperative Chemotherapy Group

Requests for reprints should be addressed to John Louis, M.D., Loyola University School of Medicine,
706 S. Wolcott St., Chicago, Ill. 60612
.

Excerpt

Early studies by the Midwest Cooperative Chemotherapy Group to determine the therapeutic spectrum for parenteral vinblastine sulfate* indicated that Hodgkin's disease was the most responsive tumor (1).

The obvious advantages of an effective oral route of administration and the knowledge that there is significant gastrointestinal absorption of vinblastine sulfate have made it desirable to define the optimal limits of oral dosage. Earlier comparative studies of the oral and parenteral routes of administration suggested that responses could be obtained by the orally administered drug in doses two to three times that of the intravenous dose. However, the wide variation in dosage

Note

The contributing institutions, number of patients (in parentheses), and investigators of the Midwest Cooperative Chemotherapy Group that participated in this study are the following:

Ohio State University (39), Wilson, H. E., Doan, C. A., Bouroncle, B., Wall, R. L.; Loyola University (13), Louis, J. (Chairman); Henry Ford Hospital (10), Monto, R., Talley, R.; VA Hines (6), Donnelly, W. J.; Cleveland Clinic (6), Battle, J., Hewlett, J.; Ellis Fischel (3), Evans, A. M.; University of Iowa (2), Fowler, W.; VA Research, Chicago (2), Linman, J. W.; Indiana University (1), Rohn, R. J., Bond, W.

Article and Author Information

Drs. Wilson and Louis are the Writing Committee for the Midwest Cooperative Chemotherapy Group. For the list of contributing institutions and investigators, see the note after the summary of this paper.
These studies were supported by research grants to the Midwest Cooperative Chemotherapy Group from Abbott Laboratories, Eli Lilly & Co., and Lederle Laboratories.
↵* The vinblastine sulfate (Velban®) used in the present study was prepared and supplied by the Eli Lilly & Co. laboratories, J. Armstrong, M.D., Indianapolis, Ind.
- Received March 8, 1967.
- Accepted March 23, 1967.